| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 90 | 2024 | 11118 | 2.580 |
Why?
|
| Prostate-Specific Antigen | 44 | 2024 | 2469 | 1.890 |
Why?
|
| Phenylthiohydantoin | 10 | 2021 | 205 | 1.580 |
Why?
|
| Androgen Antagonists | 21 | 2024 | 1410 | 1.520 |
Why?
|
| Androstenes | 10 | 2021 | 181 | 1.040 |
Why?
|
| Antineoplastic Agents, Hormonal | 15 | 2021 | 1520 | 1.000 |
Why?
|
| Receptors, Androgen | 20 | 2021 | 1079 | 0.950 |
Why?
|
| Nitriles | 18 | 2021 | 971 | 0.950 |
Why?
|
| Leuprolide | 9 | 2024 | 312 | 0.830 |
Why?
|
| Benzamides | 13 | 2021 | 1370 | 0.760 |
Why?
|
| Prostatectomy | 15 | 2024 | 1824 | 0.670 |
Why?
|
| Prostate | 10 | 2023 | 1770 | 0.600 |
Why?
|
| Taxoids | 10 | 2020 | 668 | 0.560 |
Why?
|
| Drug Repositioning | 1 | 2019 | 233 | 0.550 |
Why?
|
| Anilides | 8 | 2013 | 411 | 0.540 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 25 | 2024 | 11742 | 0.520 |
Why?
|
| Neoplastic Cells, Circulating | 5 | 2021 | 946 | 0.520 |
Why?
|
| Azasteroids | 2 | 2012 | 37 | 0.480 |
Why?
|
| Ultrasonography, Interventional | 2 | 2013 | 1496 | 0.480 |
Why?
|
| Androgens | 16 | 2024 | 1286 | 0.470 |
Why?
|
| Kallikreins | 5 | 2021 | 220 | 0.450 |
Why?
|
| Antineoplastic Agents | 18 | 2021 | 13639 | 0.440 |
Why?
|
| Sirolimus | 4 | 2012 | 1533 | 0.430 |
Why?
|
| Cisplatin | 9 | 2014 | 1651 | 0.420 |
Why?
|
| Neoadjuvant Therapy | 11 | 2023 | 2827 | 0.380 |
Why?
|
| Complementary Therapies | 3 | 2012 | 486 | 0.370 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 112 | 0.360 |
Why?
|
| Prednisone | 7 | 2024 | 1563 | 0.350 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2012 | 1148 | 0.350 |
Why?
|
| Cancer Vaccines | 3 | 2014 | 1051 | 0.350 |
Why?
|
| Adenocarcinoma | 12 | 2019 | 6346 | 0.330 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2008 | 144 | 0.320 |
Why?
|
| Tosyl Compounds | 8 | 2013 | 115 | 0.320 |
Why?
|
| Drug Resistance, Neoplasm | 10 | 2021 | 5305 | 0.310 |
Why?
|
| Testosterone | 12 | 2024 | 2472 | 0.300 |
Why?
|
| Male | 114 | 2024 | 360804 | 0.300 |
Why?
|
| Prostatic Hyperplasia | 1 | 2012 | 521 | 0.300 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 3 | 2003 | 81 | 0.270 |
Why?
|
| Phytotherapy | 1 | 2008 | 296 | 0.270 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2008 | 350 | 0.270 |
Why?
|
| Simplexvirus | 6 | 1987 | 803 | 0.260 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2009 | 1136 | 0.250 |
Why?
|
| DNA Adducts | 3 | 1999 | 94 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 10 | 2024 | 9280 | 0.240 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 3 | 2014 | 99 | 0.230 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 678 | 0.230 |
Why?
|
| Androstadienes | 3 | 2016 | 348 | 0.230 |
Why?
|
| Radium | 1 | 2024 | 72 | 0.220 |
Why?
|
| Neoplasm Proteins | 4 | 2017 | 3617 | 0.220 |
Why?
|
| Soybean Proteins | 1 | 2003 | 55 | 0.220 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 2002 | 68 | 0.210 |
Why?
|
| Humans | 126 | 2024 | 761504 | 0.210 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 2002 | 127 | 0.200 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 2007 | 416 | 0.200 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 2 | 2004 | 178 | 0.200 |
Why?
|
| DNA Damage | 6 | 1999 | 2446 | 0.190 |
Why?
|
| Immunotherapy | 3 | 2013 | 4652 | 0.190 |
Why?
|
| Plant Extracts | 2 | 2017 | 498 | 0.190 |
Why?
|
| Progesterone | 4 | 2014 | 742 | 0.190 |
Why?
|
| Thiohydantoins | 1 | 2021 | 19 | 0.190 |
Why?
|
| Orchiectomy | 7 | 2013 | 463 | 0.180 |
Why?
|
| Chemoprevention | 1 | 2003 | 326 | 0.180 |
Why?
|
| Oligopeptides | 1 | 2006 | 1187 | 0.180 |
Why?
|
| Silymarin | 2 | 2012 | 46 | 0.180 |
Why?
|
| Aged | 53 | 2024 | 169289 | 0.180 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2021 | 629 | 0.180 |
Why?
|
| Treatment Outcome | 28 | 2024 | 64680 | 0.170 |
Why?
|
| Consensus Development Conferences, NIH as Topic | 1 | 1999 | 29 | 0.170 |
Why?
|
| Fasting | 1 | 2006 | 1603 | 0.170 |
Why?
|
| Urogenital Neoplasms | 1 | 2020 | 131 | 0.170 |
Why?
|
| Isoxazoles | 1 | 2001 | 232 | 0.160 |
Why?
|
| Estramustine | 4 | 2013 | 35 | 0.160 |
Why?
|
| Prodrugs | 1 | 2000 | 261 | 0.160 |
Why?
|
| Dietary Fats | 2 | 2003 | 1995 | 0.150 |
Why?
|
| Middle Aged | 52 | 2024 | 220895 | 0.150 |
Why?
|
| Vitis | 1 | 2017 | 19 | 0.150 |
Why?
|
| DNA | 4 | 1996 | 7212 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2022 | 3492 | 0.140 |
Why?
|
| Cholesterol | 1 | 2006 | 2904 | 0.140 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2019 | 36426 | 0.140 |
Why?
|
| Aged, 80 and over | 24 | 2024 | 58976 | 0.140 |
Why?
|
| DNA, Viral | 4 | 1987 | 2202 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2012 | 2057 | 0.130 |
Why?
|
| Bromodeoxyuridine | 2 | 1987 | 311 | 0.120 |
Why?
|
| Contrast Media | 2 | 2005 | 5311 | 0.120 |
Why?
|
| Neoplasm Staging | 9 | 2021 | 11121 | 0.120 |
Why?
|
| Venous Thromboembolism | 1 | 2008 | 1866 | 0.120 |
Why?
|
| Patient Selection | 3 | 2012 | 4244 | 0.120 |
Why?
|
| DNA, Neoplasm | 6 | 2007 | 1745 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2011 | 5671 | 0.120 |
Why?
|
| Selenium | 2 | 2012 | 417 | 0.120 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2008 | 410 | 0.120 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2007 | 619 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2008 | 10445 | 0.120 |
Why?
|
| Microtubules | 1 | 2020 | 1074 | 0.120 |
Why?
|
| Ketoconazole | 2 | 2014 | 97 | 0.110 |
Why?
|
| Cell Line, Tumor | 11 | 2020 | 16981 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2008 | 3164 | 0.110 |
Why?
|
| Kidney Neoplasms | 3 | 2008 | 4249 | 0.110 |
Why?
|
| Luciferases | 5 | 2008 | 714 | 0.110 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 1994 | 97 | 0.110 |
Why?
|
| Vitamin E | 2 | 2012 | 872 | 0.110 |
Why?
|
| Urothelium | 2 | 2013 | 269 | 0.110 |
Why?
|
| Protective Agents | 1 | 2014 | 150 | 0.110 |
Why?
|
| Cytarabine | 2 | 1986 | 697 | 0.110 |
Why?
|
| Mitomycin | 1 | 2013 | 263 | 0.100 |
Why?
|
| Lythraceae | 1 | 2012 | 7 | 0.100 |
Why?
|
| Curcuma | 1 | 2012 | 10 | 0.100 |
Why?
|
| Goserelin | 1 | 2013 | 126 | 0.100 |
Why?
|
| Watchful Waiting | 2 | 2021 | 491 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2013 | 111 | 0.100 |
Why?
|
| DNA Repair | 4 | 1999 | 2045 | 0.100 |
Why?
|
| Nucleic Acid Conformation | 1 | 1996 | 902 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 9 | 2005 | 6132 | 0.100 |
Why?
|
| Pregnenolone | 1 | 2011 | 27 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2006 | 6391 | 0.100 |
Why?
|
| Disease Progression | 15 | 2016 | 13506 | 0.100 |
Why?
|
| Retreatment | 1 | 2013 | 598 | 0.100 |
Why?
|
| Stilbenes | 1 | 2012 | 155 | 0.090 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2014 | 629 | 0.090 |
Why?
|
| Genes, Reporter | 3 | 2008 | 1529 | 0.090 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2014 | 2223 | 0.090 |
Why?
|
| Benzimidazoles | 1 | 2016 | 858 | 0.090 |
Why?
|
| Finasteride | 1 | 2012 | 86 | 0.090 |
Why?
|
| Acyclovir | 2 | 1989 | 268 | 0.090 |
Why?
|
| Benzoquinones | 1 | 2011 | 198 | 0.090 |
Why?
|
| Cyclophosphamide | 4 | 1994 | 2218 | 0.090 |
Why?
|
| Immunization, Secondary | 1 | 2013 | 367 | 0.090 |
Why?
|
| Brachytherapy | 2 | 2013 | 1223 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2005 | 621 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2017 | 8547 | 0.090 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2011 | 2425 | 0.090 |
Why?
|
| Tea | 1 | 2012 | 288 | 0.090 |
Why?
|
| Protein Kinases | 2 | 2008 | 1608 | 0.090 |
Why?
|
| RNA, Messenger | 7 | 2017 | 12795 | 0.090 |
Why?
|
| Mutagens | 1 | 1991 | 179 | 0.090 |
Why?
|
| Carcinoma | 2 | 2011 | 2330 | 0.090 |
Why?
|
| Branched DNA Signal Amplification Assay | 1 | 2009 | 4 | 0.090 |
Why?
|
| Blotting, Western | 2 | 2008 | 5035 | 0.090 |
Why?
|
| Antioxidants | 2 | 2012 | 1668 | 0.080 |
Why?
|
| Stomatitis, Herpetic | 1 | 1989 | 12 | 0.080 |
Why?
|
| Risk Assessment | 6 | 2021 | 23995 | 0.080 |
Why?
|
| Lactams, Macrocyclic | 1 | 2011 | 318 | 0.080 |
Why?
|
| Neoplasm Metastasis | 7 | 2021 | 4915 | 0.080 |
Why?
|
| Cystectomy | 1 | 2014 | 634 | 0.080 |
Why?
|
| Oncogene Fusion | 1 | 2009 | 81 | 0.080 |
Why?
|
| Bone Marrow Neoplasms | 2 | 1999 | 101 | 0.080 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 6814 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2011 | 424 | 0.080 |
Why?
|
| Phytoestrogens | 1 | 2008 | 59 | 0.080 |
Why?
|
| Rectum | 1 | 2013 | 892 | 0.080 |
Why?
|
| Estrogens | 3 | 2007 | 1522 | 0.080 |
Why?
|
| Quinazolines | 2 | 2011 | 1371 | 0.080 |
Why?
|
| Hormone Antagonists | 1 | 2008 | 107 | 0.070 |
Why?
|
| G2 Phase | 1 | 2008 | 136 | 0.070 |
Why?
|
| Time Factors | 13 | 2021 | 39967 | 0.070 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 314 | 0.070 |
Why?
|
| Plant Preparations | 1 | 2008 | 94 | 0.070 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 9420 | 0.070 |
Why?
|
| Bloom Syndrome | 1 | 1987 | 10 | 0.070 |
Why?
|
| Bone Neoplasms | 3 | 2024 | 2529 | 0.070 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2014 | 782 | 0.070 |
Why?
|
| Androgen Receptor Antagonists | 2 | 2012 | 125 | 0.070 |
Why?
|
| Transvestism | 1 | 2006 | 4 | 0.070 |
Why?
|
| Mifepristone | 1 | 2008 | 151 | 0.070 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2006 | 321 | 0.070 |
Why?
|
| Piperazines | 3 | 2007 | 2523 | 0.070 |
Why?
|
| Tumor Virus Infections | 1 | 1990 | 438 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 11 | 2007 | 10766 | 0.070 |
Why?
|
| Carboplatin | 3 | 2008 | 794 | 0.070 |
Why?
|
| Mutagenesis | 1 | 1991 | 1232 | 0.070 |
Why?
|
| Drug Therapy, Combination | 4 | 2021 | 6310 | 0.070 |
Why?
|
| Beverages | 1 | 2012 | 821 | 0.070 |
Why?
|
| Hyperaldosteronism | 1 | 2010 | 247 | 0.070 |
Why?
|
| Mutation | 9 | 2017 | 30052 | 0.070 |
Why?
|
| Indoles | 1 | 1994 | 1833 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2007 | 208 | 0.070 |
Why?
|
| Molecular Sequence Data | 9 | 2009 | 17635 | 0.070 |
Why?
|
| Cell Death | 2 | 2009 | 1678 | 0.070 |
Why?
|
| Immunohistochemistry | 7 | 2017 | 11076 | 0.070 |
Why?
|
| Vaccinia virus | 2 | 2014 | 331 | 0.060 |
Why?
|
| Cell Nucleus | 2 | 2009 | 2909 | 0.060 |
Why?
|
| Enoxaparin | 1 | 2008 | 391 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2009 | 3810 | 0.060 |
Why?
|
| Base Sequence | 8 | 1997 | 12441 | 0.060 |
Why?
|
| Chymotrypsin | 1 | 2005 | 138 | 0.060 |
Why?
|
| Plasmids | 3 | 1999 | 2269 | 0.060 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2007 | 276 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2019 | 3514 | 0.060 |
Why?
|
| Estradiol Congeners | 2 | 2004 | 23 | 0.060 |
Why?
|
| CDC2 Protein Kinase | 1 | 2006 | 213 | 0.060 |
Why?
|
| Radiation Tolerance | 1 | 2008 | 479 | 0.060 |
Why?
|
| Paclitaxel | 2 | 2005 | 1732 | 0.060 |
Why?
|
| Cell Transformation, Viral | 2 | 1985 | 526 | 0.060 |
Why?
|
| Pyrimidines | 3 | 2007 | 3028 | 0.060 |
Why?
|
| Diet | 1 | 2003 | 8075 | 0.060 |
Why?
|
| Polyethylene Glycols | 2 | 2014 | 1189 | 0.060 |
Why?
|
| G1 Phase | 1 | 2006 | 403 | 0.060 |
Why?
|
| Microwaves | 1 | 2006 | 185 | 0.060 |
Why?
|
| Endpoint Determination | 1 | 2008 | 590 | 0.060 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2012 | 1606 | 0.060 |
Why?
|
| Biopsy | 6 | 2017 | 6766 | 0.060 |
Why?
|
| Mitoxantrone | 2 | 2003 | 148 | 0.060 |
Why?
|
| Mucin-1 | 1 | 2009 | 540 | 0.060 |
Why?
|
| Diethylstilbestrol | 1 | 2004 | 87 | 0.060 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 266 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2009 | 2919 | 0.060 |
Why?
|
| Adjuvants, Pharmaceutic | 1 | 2023 | 48 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2005 | 265 | 0.060 |
Why?
|
| Reference Values | 2 | 2002 | 4920 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 15266 | 0.060 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 2 | 1996 | 110 | 0.060 |
Why?
|
| Thymine Nucleotides | 1 | 2003 | 57 | 0.060 |
Why?
|
| Vitamins | 1 | 2012 | 1635 | 0.060 |
Why?
|
| Flutamide | 3 | 1999 | 95 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2014 | 1115 | 0.050 |
Why?
|
| Prospective Studies | 11 | 2021 | 54425 | 0.050 |
Why?
|
| Drug Contamination | 1 | 2004 | 152 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2006 | 3597 | 0.050 |
Why?
|
| Camptothecin | 1 | 2006 | 591 | 0.050 |
Why?
|
| Neoplasm, Residual | 2 | 2019 | 1008 | 0.050 |
Why?
|
| Carbohydrate Metabolism | 1 | 2003 | 263 | 0.050 |
Why?
|
| Mice, Nude | 3 | 2020 | 3615 | 0.050 |
Why?
|
| Warfarin | 2 | 2008 | 1483 | 0.050 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2023 | 1784 | 0.050 |
Why?
|
| Combined Modality Therapy | 4 | 2021 | 8529 | 0.050 |
Why?
|
| Recombination, Genetic | 1 | 1987 | 1519 | 0.050 |
Why?
|
| Drug Resistance, Multiple | 1 | 2003 | 255 | 0.050 |
Why?
|
| Animals | 19 | 2020 | 168459 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 4026 | 0.050 |
Why?
|
| Cardiac Tamponade | 1 | 1983 | 175 | 0.050 |
Why?
|
| Cell Division | 3 | 2001 | 4465 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 1989 | 1189 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2007 | 1934 | 0.050 |
Why?
|
| Oligonucleotides, Antisense | 1 | 2004 | 461 | 0.050 |
Why?
|
| Hydrocortisone | 1 | 2009 | 1819 | 0.050 |
Why?
|
| Sarcoma, Kaposi | 1 | 2004 | 374 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 2 | 2017 | 1802 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 6484 | 0.050 |
Why?
|
| RNA Splicing | 2 | 2014 | 918 | 0.050 |
Why?
|
| Morpholines | 1 | 2004 | 581 | 0.050 |
Why?
|
| Transcription, Genetic | 7 | 2006 | 7594 | 0.050 |
Why?
|
| Androstenols | 2 | 2011 | 25 | 0.050 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2022 | 297 | 0.050 |
Why?
|
| Transcription Factors | 5 | 2006 | 12128 | 0.050 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 662 | 0.050 |
Why?
|
| Point Mutation | 2 | 1997 | 1595 | 0.050 |
Why?
|
| Primary Myelofibrosis | 1 | 1983 | 209 | 0.050 |
Why?
|
| Salvage Therapy | 2 | 2023 | 1264 | 0.050 |
Why?
|
| Mice | 14 | 2020 | 81525 | 0.050 |
Why?
|
| New Zealand | 1 | 2021 | 358 | 0.040 |
Why?
|
| Gynecomastia | 1 | 2021 | 87 | 0.040 |
Why?
|
| Alkynes | 1 | 2001 | 320 | 0.040 |
Why?
|
| Phthalazines | 1 | 2022 | 383 | 0.040 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 3688 | 0.040 |
Why?
|
| Cell Survival | 4 | 2007 | 5791 | 0.040 |
Why?
|
| Risk | 2 | 2021 | 9610 | 0.040 |
Why?
|
| Pilot Projects | 3 | 2004 | 8631 | 0.040 |
Why?
|
| Body Fat Distribution | 1 | 2021 | 245 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2007 | 1626 | 0.040 |
Why?
|
| Sulfonamides | 2 | 2006 | 1978 | 0.040 |
Why?
|
| Base Pair Mismatch | 1 | 1999 | 92 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2014 | 4853 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2003 | 857 | 0.040 |
Why?
|
| Steroid 16-alpha-Hydroxylase | 1 | 2018 | 12 | 0.040 |
Why?
|
| Radiography | 3 | 2016 | 6965 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 1303 | 0.040 |
Why?
|
| Pyrazoles | 2 | 2006 | 2009 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2021 | 551 | 0.040 |
Why?
|
| Cell Line | 9 | 2006 | 15601 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2006 | 1062 | 0.040 |
Why?
|
| Flow Cytometry | 2 | 2008 | 5869 | 0.040 |
Why?
|
| Guidelines as Topic | 2 | 2008 | 1386 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 2 | 2007 | 2645 | 0.040 |
Why?
|
| Oxygen | 2 | 2005 | 4227 | 0.040 |
Why?
|
| Glucuronides | 1 | 2017 | 20 | 0.040 |
Why?
|
| Imidazolidines | 1 | 1997 | 38 | 0.040 |
Why?
|
| Australia | 1 | 2021 | 1250 | 0.040 |
Why?
|
| Peptides | 1 | 2009 | 4358 | 0.040 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2021 | 549 | 0.040 |
Why?
|
| Transfection | 5 | 2005 | 5774 | 0.040 |
Why?
|
| Interleukin-2 | 1 | 2004 | 1889 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1999 | 379 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2018 | 244 | 0.040 |
Why?
|
| Ribonucleosides | 2 | 1987 | 79 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2009 | 4575 | 0.030 |
Why?
|
| Testosterone Congeners | 1 | 2017 | 62 | 0.030 |
Why?
|
| Lipid Peroxidation | 1 | 2017 | 271 | 0.030 |
Why?
|
| Structure-Activity Relationship | 2 | 2006 | 3076 | 0.030 |
Why?
|
| Double-Blind Method | 3 | 2021 | 12341 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2008 | 2321 | 0.030 |
Why?
|
| Meta-Analysis as Topic | 1 | 2001 | 1380 | 0.030 |
Why?
|
| Carcinogens, Environmental | 1 | 1996 | 72 | 0.030 |
Why?
|
| Sulfates | 1 | 2017 | 380 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2013 | 2645 | 0.030 |
Why?
|
| Androstenedione | 2 | 2011 | 131 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2021 | 1093 | 0.030 |
Why?
|
| Killer Cells, Natural | 2 | 2004 | 2200 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 9000 | 0.030 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 9606 | 0.030 |
Why?
|
| Hormones | 1 | 2000 | 869 | 0.030 |
Why?
|
| United States | 5 | 2022 | 72334 | 0.030 |
Why?
|
| Chromium | 1 | 1996 | 132 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2003 | 1186 | 0.030 |
Why?
|
| Kidney Pelvis | 1 | 1996 | 186 | 0.030 |
Why?
|
| Prognosis | 3 | 2011 | 29625 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 8002 | 0.030 |
Why?
|
| Adult | 15 | 2019 | 221177 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2008 | 3415 | 0.030 |
Why?
|
| Cyclohexenes | 1 | 1994 | 15 | 0.030 |
Why?
|
| Fowlpox virus | 1 | 2014 | 21 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2005 | 3769 | 0.030 |
Why?
|
| Butyrates | 1 | 1996 | 169 | 0.030 |
Why?
|
| Rare Diseases | 1 | 2020 | 622 | 0.030 |
Why?
|
| Skin Neoplasms | 2 | 2005 | 5821 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 2226 | 0.030 |
Why?
|
| Ribavirin | 2 | 1987 | 395 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2009 | 2932 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2017 | 594 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2005 | 2047 | 0.030 |
Why?
|
| Xeroderma Pigmentosum | 1 | 1994 | 31 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 2017 | 552 | 0.030 |
Why?
|
| Multivariate Analysis | 4 | 2011 | 12059 | 0.030 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 428 | 0.030 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 39106 | 0.030 |
Why?
|
| Filgrastim | 1 | 2014 | 132 | 0.030 |
Why?
|
| Benzofurans | 1 | 1994 | 139 | 0.030 |
Why?
|
| Neoplasm Transplantation | 3 | 2006 | 2016 | 0.030 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 1994 | 140 | 0.030 |
Why?
|
| Testis | 1 | 2017 | 794 | 0.030 |
Why?
|
| Administration, Intravesical | 1 | 2013 | 92 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2017 | 10209 | 0.030 |
Why?
|
| DNA Primers | 2 | 1996 | 2819 | 0.030 |
Why?
|
| Risk Factors | 4 | 2021 | 74206 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 503 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 1996 | 458 | 0.030 |
Why?
|
| Nitroimidazoles | 2 | 1991 | 117 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2001 | 3162 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2004 | 18965 | 0.030 |
Why?
|
| Vinblastine | 1 | 2014 | 488 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2017 | 1702 | 0.030 |
Why?
|
| Genome, Human | 2 | 2017 | 4425 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 4 | 2007 | 6075 | 0.030 |
Why?
|
| Retrospective Studies | 4 | 2023 | 80636 | 0.030 |
Why?
|
| Arginine | 1 | 1996 | 934 | 0.030 |
Why?
|
| Fibrosarcoma | 2 | 1991 | 309 | 0.020 |
Why?
|
| Remission Induction | 3 | 2006 | 2396 | 0.020 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 9539 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2005 | 3548 | 0.020 |
Why?
|
| Research Design | 1 | 2008 | 6180 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1092 | 0.020 |
Why?
|
| Quality of Life | 2 | 2011 | 13367 | 0.020 |
Why?
|
| Osteoporosis | 1 | 2001 | 1606 | 0.020 |
Why?
|
| Body Composition | 1 | 2021 | 2426 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2011 | 95 | 0.020 |
Why?
|
| Endonucleases | 1 | 2014 | 371 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2014 | 891 | 0.020 |
Why?
|
| Genes, Suppressor | 1 | 1991 | 47 | 0.020 |
Why?
|
| Indomethacin | 1 | 2011 | 325 | 0.020 |
Why?
|
| Ultraviolet Rays | 2 | 1987 | 1080 | 0.020 |
Why?
|
| DNA Replication | 2 | 1991 | 1418 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2001 | 3550 | 0.020 |
Why?
|
| Alkylating Agents | 1 | 1991 | 133 | 0.020 |
Why?
|
| Acute Disease | 1 | 2001 | 7237 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2010 | 2927 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 4580 | 0.020 |
Why?
|
| Dehydroepiandrosterone | 1 | 2011 | 258 | 0.020 |
Why?
|
| Cholestenone 5 alpha-Reductase | 1 | 2009 | 21 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2000 | 2557 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2016 | 10090 | 0.020 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1992 | 783 | 0.020 |
Why?
|
| Leukapheresis | 1 | 1990 | 134 | 0.020 |
Why?
|
| Retroviridae Infections | 1 | 1990 | 147 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2003 | 14666 | 0.020 |
Why?
|
| Piperidines | 2 | 2011 | 1656 | 0.020 |
Why?
|
| DNA Helicases | 1 | 2014 | 851 | 0.020 |
Why?
|
| Plasmapheresis | 1 | 1990 | 206 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 3 | 2005 | 3734 | 0.020 |
Why?
|
| Cytokines | 1 | 2004 | 7396 | 0.020 |
Why?
|
| Reproducibility of Results | 2 | 2004 | 20098 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 384 | 0.020 |
Why?
|
| Genotype | 2 | 2017 | 12990 | 0.020 |
Why?
|
| Gene Expression | 2 | 2017 | 7581 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 1989 | 367 | 0.020 |
Why?
|
| Castration | 1 | 2008 | 151 | 0.020 |
Why?
|
| Chromogranin A | 1 | 2008 | 49 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 3778 | 0.020 |
Why?
|
| Dihydrotestosterone | 2 | 2000 | 195 | 0.020 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1991 | 507 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2017 | 22176 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 1334 | 0.020 |
Why?
|
| AIDS-Related Complex | 1 | 1987 | 107 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2011 | 4124 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2008 | 127 | 0.020 |
Why?
|
| Oligonucleotides | 1 | 1991 | 582 | 0.020 |
Why?
|
| Bone Marrow | 4 | 2005 | 2911 | 0.020 |
Why?
|
| Burkitt Lymphoma | 1 | 1990 | 335 | 0.020 |
Why?
|
| Age Factors | 2 | 2001 | 18395 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 2224 | 0.020 |
Why?
|
| Methotrexate | 1 | 2014 | 1719 | 0.020 |
Why?
|
| Phorbol Esters | 1 | 1987 | 108 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 9177 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2007 | 41487 | 0.020 |
Why?
|
| Thymidine Kinase | 2 | 1985 | 286 | 0.020 |
Why?
|
| Vero Cells | 1 | 1987 | 482 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 1989 | 497 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 1989 | 432 | 0.020 |
Why?
|
| Carbon Dioxide | 1 | 1991 | 1147 | 0.020 |
Why?
|
| Administration, Oral | 2 | 2004 | 4021 | 0.020 |
Why?
|
| Teratoma | 1 | 1989 | 404 | 0.020 |
Why?
|
| Genes, Viral | 1 | 1987 | 649 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2007 | 767 | 0.020 |
Why?
|
| Hydroxysteroid Dehydrogenases | 1 | 2006 | 29 | 0.020 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2006 | 34 | 0.020 |
Why?
|
| Bone and Bones | 2 | 2011 | 2568 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2006 | 203 | 0.020 |
Why?
|
| Hydroxyprostaglandin Dehydrogenases | 1 | 2006 | 31 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 1646 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2017 | 2917 | 0.020 |
Why?
|
| Estradiol | 3 | 2000 | 1937 | 0.020 |
Why?
|
| ras Proteins | 1 | 2011 | 1054 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 3595 | 0.020 |
Why?
|
| Etoposide | 2 | 2002 | 634 | 0.020 |
Why?
|
| Goats | 1 | 2005 | 165 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2010 | 1626 | 0.020 |
Why?
|
| Fluorocarbons | 1 | 1991 | 492 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 8465 | 0.020 |
Why?
|
| Eosinophilia | 1 | 1990 | 560 | 0.020 |
Why?
|
| Antibodies | 2 | 2005 | 2418 | 0.020 |
Why?
|
| Chromosome Deletion | 1 | 1989 | 1386 | 0.010 |
Why?
|
| Random Allocation | 1 | 1989 | 2395 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1990 | 705 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 6534 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 1985 | 206 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2005 | 426 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 1 | 1990 | 1078 | 0.010 |
Why?
|
| Guanine | 1 | 1985 | 279 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 1985 | 395 | 0.010 |
Why?
|
| Chromatin | 1 | 1996 | 2960 | 0.010 |
Why?
|
| Ethinyl Estradiol | 1 | 2004 | 113 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 318 | 0.010 |
Why?
|
| Papillomaviridae | 1 | 1990 | 1119 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 615 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 2231 | 0.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2011 | 1745 | 0.010 |
Why?
|
| Drug Combinations | 2 | 2005 | 2048 | 0.010 |
Why?
|
| Laminin | 1 | 2005 | 408 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1989 | 799 | 0.010 |
Why?
|
| Purines | 1 | 2006 | 607 | 0.010 |
Why?
|
| Sterol Regulatory Element Binding Protein 1 | 1 | 2003 | 135 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2005 | 361 | 0.010 |
Why?
|
| Lung | 2 | 2005 | 10000 | 0.010 |
Why?
|
| Kinetics | 2 | 2004 | 6374 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 1989 | 1768 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2002 | 42 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1990 | 1374 | 0.010 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2002 | 40 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 597 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1990 | 1378 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 1990 | 2693 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2006 | 1880 | 0.010 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2003 | 286 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6228 | 0.010 |
Why?
|
| Fibroblasts | 2 | 1996 | 4141 | 0.010 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2014 | 3639 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 1987 | 2199 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2005 | 1693 | 0.010 |
Why?
|
| Neoplasms | 2 | 1990 | 22170 | 0.010 |
Why?
|
| Cyclization | 1 | 2001 | 59 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2005 | 803 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2009 | 2141 | 0.010 |
Why?
|
| Maximum Tolerated Dose | 1 | 2004 | 883 | 0.010 |
Why?
|
| Female | 10 | 2020 | 392644 | 0.010 |
Why?
|
| Etanidazole | 2 | 1991 | 22 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2009 | 3602 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 1991 | 3395 | 0.010 |
Why?
|
| Biological Transport | 1 | 2005 | 2091 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 2 | 2005 | 4740 | 0.010 |
Why?
|
| Cell Communication | 1 | 2008 | 1657 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 727 | 0.010 |
Why?
|
| Hypertension | 1 | 2021 | 8540 | 0.010 |
Why?
|
| Carmustine | 2 | 1991 | 138 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 1541 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2009 | 6216 | 0.010 |
Why?
|
| Glucocorticoids | 1 | 2010 | 2161 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2005 | 1687 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2002 | 336 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2011 | 15936 | 0.010 |
Why?
|
| DNA, Recombinant | 1 | 2000 | 455 | 0.010 |
Why?
|
| Spectrophotometry, Atomic | 1 | 1999 | 82 | 0.010 |
Why?
|
| Janus Kinase 1 | 1 | 1999 | 107 | 0.010 |
Why?
|
| Amino Acids | 1 | 2005 | 1718 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2001 | 778 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2006 | 1499 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2011 | 4511 | 0.010 |
Why?
|
| Area Under Curve | 1 | 2003 | 1638 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1994 | 12974 | 0.010 |
Why?
|
| Pericardium | 1 | 1983 | 675 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2004 | 3093 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 2078 | 0.010 |
Why?
|
| Virus Replication | 1 | 1986 | 2435 | 0.010 |
Why?
|
| Transgenes | 1 | 2001 | 1010 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 2000 | 750 | 0.010 |
Why?
|
| Diarrhea | 1 | 2004 | 1318 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2009 | 13446 | 0.010 |
Why?
|
| Tachycardia | 1 | 2000 | 600 | 0.010 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 1999 | 368 | 0.010 |
Why?
|
| Bone Remodeling | 1 | 2001 | 581 | 0.010 |
Why?
|
| Temperature | 1 | 2004 | 2226 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1990 | 2298 | 0.010 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2000 | 550 | 0.010 |
Why?
|
| Codon | 1 | 1999 | 601 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 12463 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2004 | 2113 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2006 | 2865 | 0.010 |
Why?
|
| Models, Biological | 1 | 2013 | 9469 | 0.010 |
Why?
|
| Survival Rate | 2 | 2007 | 12725 | 0.010 |
Why?
|
| Binding Sites | 1 | 2005 | 6055 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2000 | 1900 | 0.010 |
Why?
|
| Drug Synergism | 2 | 1991 | 1755 | 0.010 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 1997 | 150 | 0.010 |
Why?
|
| Collagen | 1 | 2005 | 2638 | 0.010 |
Why?
|
| Signal Transduction | 2 | 2013 | 23445 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 1997 | 574 | 0.010 |
Why?
|
| Mitochondria | 1 | 2009 | 3624 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2004 | 2612 | 0.010 |
Why?
|
| Th2 Cells | 1 | 2001 | 1060 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2000 | 1089 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2000 | 702 | 0.010 |
Why?
|
| Rabbits | 1 | 2002 | 4772 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2006 | 8320 | 0.010 |
Why?
|
| Lymphocyte Activation | 2 | 2001 | 5486 | 0.010 |
Why?
|
| S Phase | 1 | 1996 | 421 | 0.010 |
Why?
|
| Steroids | 1 | 2000 | 929 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 2510 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1990 | 4320 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2005 | 4544 | 0.010 |
Why?
|
| Bone Marrow Diseases | 1 | 1995 | 233 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 1996 | 687 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2001 | 2208 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 1997 | 1738 | 0.010 |
Why?
|
| Logistic Models | 1 | 2007 | 13255 | 0.010 |
Why?
|
| Fever | 1 | 2000 | 1618 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1995 | 1991 | 0.010 |
Why?
|
| Thiotepa | 1 | 1991 | 66 | 0.010 |
Why?
|
| Imidazoles | 1 | 1997 | 1180 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 4484 | 0.010 |
Why?
|
| Pyridines | 1 | 2003 | 2875 | 0.010 |
Why?
|
| Colony-Forming Units Assay | 1 | 1991 | 352 | 0.010 |
Why?
|
| Forecasting | 1 | 2000 | 2928 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 1999 | 4111 | 0.010 |
Why?
|
| Endometrial Neoplasms | 1 | 1999 | 1366 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1991 | 915 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2001 | 3673 | 0.010 |
Why?
|
| Organoplatinum Compounds | 1 | 1991 | 407 | 0.010 |
Why?
|
| Melphalan | 1 | 1991 | 420 | 0.010 |
Why?
|
| Plasma Exchange | 1 | 1990 | 158 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1989 | 777 | 0.000 |
Why?
|
| Phenotype | 1 | 1987 | 16591 | 0.000 |
Why?
|
| Anticoagulants | 1 | 2004 | 4812 | 0.000 |
Why?
|
| Kidney | 1 | 1984 | 7048 | 0.000 |
Why?
|
| Blood Volume | 1 | 1990 | 547 | 0.000 |
Why?
|
| Genetic Markers | 1 | 1994 | 2601 | 0.000 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1991 | 718 | 0.000 |
Why?
|
| Bone Density | 1 | 2001 | 3551 | 0.000 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1989 | 1302 | 0.000 |
Why?
|
| Ultrasonography | 1 | 2001 | 5972 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 2005 | 7856 | 0.000 |
Why?
|
| Odds Ratio | 1 | 2000 | 9646 | 0.000 |
Why?
|
| Drug Evaluation | 1 | 1987 | 641 | 0.000 |
Why?
|
| Hematocrit | 1 | 1987 | 623 | 0.000 |
Why?
|
| Melanoma | 1 | 2005 | 5709 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1990 | 1596 | 0.000 |
Why?
|
| Thymidine | 1 | 1985 | 299 | 0.000 |
Why?
|
| Apoptosis | 1 | 2001 | 9486 | 0.000 |
Why?
|
| Deoxyguanosine | 1 | 1985 | 93 | 0.000 |
Why?
|
| Ganciclovir | 1 | 1985 | 252 | 0.000 |
Why?
|
| Opportunistic Infections | 1 | 1987 | 376 | 0.000 |
Why?
|
| Syndrome | 1 | 1990 | 3267 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 17904 | 0.000 |
Why?
|
| Bone Marrow Cells | 1 | 1991 | 2416 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2000 | 12953 | 0.000 |
Why?
|
| Deoxycytidine | 1 | 1985 | 877 | 0.000 |
Why?
|
| HIV | 1 | 1987 | 1582 | 0.000 |
Why?
|
| Colorectal Neoplasms | 1 | 1999 | 6935 | 0.000 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1991 | 3396 | 0.000 |
Why?
|
| Breast Neoplasms | 1 | 2001 | 21012 | 0.000 |
Why?
|
| Child, Preschool | 1 | 1996 | 42230 | 0.000 |
Why?
|
| Adolescent | 1 | 1990 | 88319 | 0.000 |
Why?
|